Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection : A multicentre cohort study
© 2023 Wiley Periodicals LLC..
The aim of this study is to investigate the effectiveness of prolonged versus standard course oseltamivir treatment among critically ill patients with severe influenza. A retrospective study of a prospectively collected database including adults with influenza infection admitted to 184 intensive care units (ICUs) in Spain from 2009 to 2018. Prolonged oseltamivir was defined if patients received the treatment beyond 5 days, whereas the standard-course group received oseltamivir for 5 days. The primary outcome was all-cause ICU mortality. Propensity score matching (PSM) was constructed, and the outcome was investigated through Cox regression and RCSs. Two thousand three hundred and ninety-seven subjects were included, of whom 1943 (81.1%) received prolonged oseltamivir and 454 (18.9%) received standard treatment. An optimal full matching algorithm was performed by matching 2171 patients, 1750 treated in the prolonged oseltamivir group and 421 controls in the standard oseltamivir group. After PSM, 387 (22.1%) patients in the prolonged oseltamivir and 119 (28.3%) patients in the standard group died (p = 0.009). After adjusting confounding factors, prolonged oseltamivir significantly reduced ICU mortality (odds ratio [OR]: 0.53, 95% confidence interval [CI]: 0.40-0.69). Prolonged oseltamivir may have protective effects on survival at Day 10 compared with a standard treatment course. Sensitivity analysis confirmed these findings. Compared with standard treatment, prolonged oseltamivir was associated with reduced ICU mortality in critically ill patients with severe influenza. Clinicians should consider extending the oseltamivir treatment duration to 10 days, particularly in higher-risk groups of prolonged viral shedding. Further randomized controlled trials are warranted to confirm these findings.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
---|---|
Enthalten in: |
Journal of medical virology - 95(2023), 8 vom: 16. Aug., Seite e29010 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Moreno, Gerard [VerfasserIn] |
---|
Links: |
---|
Themen: |
20O93L6F9H |
---|
Anmerkungen: |
Date Completed 07.08.2023 Date Revised 09.08.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.29010 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360374778 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM360374778 | ||
003 | DE-627 | ||
005 | 20231226082900.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.29010 |2 doi | |
028 | 5 | 2 | |a pubmed24n1201.xml |
035 | |a (DE-627)NLM360374778 | ||
035 | |a (NLM)37537755 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Moreno, Gerard |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection |b A multicentre cohort study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.08.2023 | ||
500 | |a Date Revised 09.08.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 Wiley Periodicals LLC. | ||
520 | |a The aim of this study is to investigate the effectiveness of prolonged versus standard course oseltamivir treatment among critically ill patients with severe influenza. A retrospective study of a prospectively collected database including adults with influenza infection admitted to 184 intensive care units (ICUs) in Spain from 2009 to 2018. Prolonged oseltamivir was defined if patients received the treatment beyond 5 days, whereas the standard-course group received oseltamivir for 5 days. The primary outcome was all-cause ICU mortality. Propensity score matching (PSM) was constructed, and the outcome was investigated through Cox regression and RCSs. Two thousand three hundred and ninety-seven subjects were included, of whom 1943 (81.1%) received prolonged oseltamivir and 454 (18.9%) received standard treatment. An optimal full matching algorithm was performed by matching 2171 patients, 1750 treated in the prolonged oseltamivir group and 421 controls in the standard oseltamivir group. After PSM, 387 (22.1%) patients in the prolonged oseltamivir and 119 (28.3%) patients in the standard group died (p = 0.009). After adjusting confounding factors, prolonged oseltamivir significantly reduced ICU mortality (odds ratio [OR]: 0.53, 95% confidence interval [CI]: 0.40-0.69). Prolonged oseltamivir may have protective effects on survival at Day 10 compared with a standard treatment course. Sensitivity analysis confirmed these findings. Compared with standard treatment, prolonged oseltamivir was associated with reduced ICU mortality in critically ill patients with severe influenza. Clinicians should consider extending the oseltamivir treatment duration to 10 days, particularly in higher-risk groups of prolonged viral shedding. Further randomized controlled trials are warranted to confirm these findings | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a ICU mortality | |
650 | 4 | |a critically ill | |
650 | 4 | |a prolonged oseltamivir | |
650 | 4 | |a severe influenza | |
650 | 7 | |a Oseltamivir |2 NLM | |
650 | 7 | |a 20O93L6F9H |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
700 | 1 | |a Carbonell, Raquel |e verfasserin |4 aut | |
700 | 1 | |a Díaz, Emili |e verfasserin |4 aut | |
700 | 1 | |a Martín-Loeches, Ignacio |e verfasserin |4 aut | |
700 | 1 | |a Restrepo, Marcos I |e verfasserin |4 aut | |
700 | 1 | |a Reyes, Luis F |e verfasserin |4 aut | |
700 | 1 | |a Solé-Violán, Jordi |e verfasserin |4 aut | |
700 | 1 | |a Bodí, María |e verfasserin |4 aut | |
700 | 1 | |a Canadell, Laura |e verfasserin |4 aut | |
700 | 1 | |a Guardiola, Juan |e verfasserin |4 aut | |
700 | 1 | |a Trefler, Sandra |e verfasserin |4 aut | |
700 | 1 | |a Vidaur, Loreto |e verfasserin |4 aut | |
700 | 1 | |a Papiol, Elisabeth |e verfasserin |4 aut | |
700 | 1 | |a Socias, Lorenzo |e verfasserin |4 aut | |
700 | 1 | |a Correig, Eudald |e verfasserin |4 aut | |
700 | 1 | |a Marín-Corral, Judith |e verfasserin |4 aut | |
700 | 1 | |a Rodríguez, Alejandro |e verfasserin |4 aut | |
700 | 0 | |a GETGAG Working Group |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 95(2023), 8 vom: 16. Aug., Seite e29010 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:95 |g year:2023 |g number:8 |g day:16 |g month:08 |g pages:e29010 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29010 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 95 |j 2023 |e 8 |b 16 |c 08 |h e29010 |